What question did this study set out to answer?

To identify and validate targets in the tumor microenvironment (TME) for antibody-drug conjugates.

Targeting Extracellular Matrix in Tumor Microenvironment with Antibody-Drug Conjugate

View Full Paper

Ask AI

Bookmark

To identify and validate targets in the tumor microenvironment (TME) for antibody-drug conjugates.
Performed proteomic analysis of decellularized tumor tissues to characterize ECM proteins.
Conducted pan-cancer transcriptomic profiling of CAF-associated ECM genes.
Developed antibodies against a TME-specific antigen EGTX004 found in multiple solid tumors.
Evaluated efficacy of EGTX004 ADC in vitro using a transwell-based tumor cell cytotoxicity assay.
Identified EGTX004 as a target consistently upregulated in multiple solid tumor types.
Confirmed elevated expression of EGTX004 early in tumorigenesis and increasing levels with tumor invasiveness.
Demonstrated positive target engagement of EGTX004 ADCs with nanomolar affinities.
Showed that EGTX004 ADCs exhibited significant tumor-killing activity in vitro.

No takes yet. Share an insight, caveat, or question.

Demonstrates anti-tumor activity of a novel antibody-drug conjugate targeting ECM in solid tumors, suggesting a new treatment approach.

Edwards et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark